Quantcast
Home / DC News / FDA: Chantix linked to adverse cardiovascular events

FDA: Chantix linked to adverse cardiovascular events

The quit-smoking drug Chantix may be associated with a small, increased risk of adverse cardiovascular events in patients with heart disease, according to the Food and Drug Administration.